Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

The neurosensory retina emerges as a prominent site of Alzheimer's disease (AD)
pathology. As a CNS extension of the brain, the neuro retina is easily accessible for …

In vivo gold standard for the ante-mortem assessment of brain β-amyloid pathology is
currently β-amyloid positron emission tomography or cerebrospinal fluid measures of β …

A variety of Alzheimer's disease (AD) mouse models overexpress mutant forms of human
amyloid precursor protein (APP), producing high levels of amyloid β (Aβ) and forming …

Este artigo apresenta o consenso realizado pelo Departamento Científico de Neurologia
Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia sobre os critérios …

The development of early non-invasive diagnosis methods and identification of novel
biomarkers are necessary for managing Alzheimer's disease (AD) and facilitating effective …

Purpose The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer's
disease (AD) and the continued discussions around that decision have increased interest in …

Amyloid plaques and tau tangles are pathological hallmarks of Alzheimer's disease (AD).
Parkinson's disease (PD) results from the accumulation of α-synuclein. TAR DNA-binding …

Accurate, reliable, and objective biomarkers for Alzheimer's disease (AD), Parkinson's
disease (PD), and related age‐associated neurodegenerative disorders are urgently …

Alzheimer's disease (AD) is of great cause for concern in our ageing population, which
currently lacks diagnostic tools to permit accurate and timely diagnosis for affected …